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ABSTRACT
Background. The significance of perineural (PNI), lym-
phatic (LI) and venous invasion (VI) in gastric cancer
patients who have received neoadjuvant chemotherapy is
unclear. The aim of this study is to determine the incidence
and prognostic significance of LI, VI and PNI in these
patients.
Patients and Methods. Consecutive patients treated with
neoadjuvant chemotherapy followed by gastrectomy with
D2 lymphadenectomy were reviewed. Presence of LI, VI
and PNI was recorded and correlated with clinical
outcomes.
Results. A total of 243 patients underwent gastrectomy
after neoadjuvant therapy for gastric adenocarcinoma. LI
was identified in 129 (53%), VI in 107 (44%) and PNI in
116 (48%) of patients. Presence of LI (HR, 2.95, CI
1.91–4.56), VI (HR, 2.66, CI 1.78–3.98) and PNI (HR,
3.85, CI 2.49–5.95) was associated with poorer survival (all
p\ 0.001). Multivariable analysis revealed that ypT stage
(HR, 1.35, CI 1.05–1.74), ypN stage (HR, 1.53, CI
1.28–1.83) and PNI (HR, 2.11, CI 1.31–3.42) were inde-
pendent predictors of survival.
Conclusions. LI, VI and PNI are associated with poorer
survival, with PNI having prognostic significance inde-
pendent of lymph node status. These factors may be useful
for further prognostication, in particular when multiple
factors are present, and appear especially useful for prog-
nostic stratification in patients with no nodal involvement.
Gastric cancer is an aggressive malignancy with over
950,000 new cases reported globally, making it the third
commonest cause of cancer death.1 In patients with
potentially curative disease, treatment usually includes
surgery with chemotherapy. In the UK, this is commonly
administered both pre- and post-operatively as part of
multimodal treatment, following the results of the MAGIC
trial.2 Pre-operative clinical staging influences whether
multimodal treatment is used and may guide prognosis.
Further accuracy of staging is possible after pathological
examination of the resected specimen3 with depth of
tumour invasion and extent of lymph node involvement
considered core prognostic factors that are incorporated
into the TNM cancer staging systems.4 Other prognostic
factors that have been identified in multiple cancers include
lymphatic vessel invasion (LI), blood vessel or venous
invasion (VI) and perineural invasion (PNI),5 although in
gastric cancer, most large studies have only reported results
from patients who had surgery alone.6–8
The use of neoadjuvant therapy adds an important
additional variable to the interpretation of the pathological
examination which may differ from the prognostic data
based on studies of patients who did not have pre-operative
chemotherapy. Whilst data have been published to aid
interpretation of post-neoadjuvant TNM staging, limited
data are available for interpretation of other important
histological findings such as lymphatic, vascular and per-
ineural invasion (LVPNI), factors which are not included in
the current international staging system (TNM 8th
edition).9
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The aim of this study is to assess the incidence and
prognostic significance of LI, VI and PNI in a consecutive
series of patients with gastric adenocarcinoma who
received neoadjuvant therapy followed by gastrectomy
with D2 lymphadenectomy at a single institution.
PATIENTS AND METHODS
Patient Population
A contemporaneously maintained database of all
patients with adenocarcinoma of the stomach was
reviewed. All patients were discussed by the multidisci-
plinary team. Patients were included in this study if they
had received neoadjuvant chemotherapy followed by either
subtotal gastrectomy with D2 lymphadenectomy or total
gastrectomy with D2 lymphadenectomy at the Northern
Oesophagogastric Cancer Unit, Newcastle upon Tyne
between 2003 and 2016. Patients were excluded if they had
received surgery with palliative intent or if they died during
their admission or within 90 days of surgery. Data
including baseline demographics (age, gender, stage of
disease and use of neoadjuvant treatment) were prospec-
tively recorded on a standardised proforma.
Disease Staging
Initial staging comprised endoscopy with biopsy and
computed tomography (CT) scans of thorax, abdomen and
pelvis. Staging laparoscopy was performed routinely in
patients thought to have locally advanced disease. Endo-
scopic ultrasound or positron emission tomography (PET)
CT were not part of the initial staging but were performed
in some cases. Patients deemed to have histologically
proven locally advanced disease (cT1/2, N ? or T3 ? , N
any) without metastasis were considered for neoadjuvant
treatment followed by resection. Patients with metastasis,
tumours deemed unresectable during surgery or macro-
scopically incomplete (palliative) resections (R2) were
excluded. The current UICC TNM 8th edition was used to
stage all patients.9
Neoadjuvant Treatment
Multiple neoadjuvant chemotherapy regimens were used
throughout the present study. The majority of patients
received epirubicin and cisplatin with either 5-fluorouracil
or capecitabine (ECF/ECX) (193 patients) or alternatively
epirubicin, oxaliplatin and capecitabine (EOX) (9 patients)
as per the MAGIC protocol.2 Nine patients received cis-
platin and 5-fluorouracil (CF), 7 patients other
combinations including 5-fluorouracil and, in 25 patients,
neoadjuvant regimen was not recorded. Adjuvant treatment
was planned in all patients receiving multi-modal treatment
as per the MAGIC protocol.
Surgical Technique
Resections were carried out using a standardised open
approach with a radical en bloc D2 lymphadenectomy.10
Proximal tumours and patients diagnosed with diffuse-type
disease were treated with total gastrectomy. Patients with a
distal tumour where adequate clearance could be achieved
received subtotal gastrectomy.
Histopathological Analysis
Specimens were resected en bloc, and immediately post-
surgery, a back-table dissection was carried out by the
operating surgeon for each lymph node station. These were
sent in separate containers to the pathology department.
Surgical specimens were fixed for 24 h in 10% formalin
before sectioning. At least four blocks with tumour and
adjacent benign peri-tumoral tissue were selected for
histopathological evaluation and immunohistochemical
staining. When no evidence of residual macroscopic
tumour was identified, the specimens were more widely
sampled.
Reporting was carried out by a team of specialist gas-
trointestinal pathologists and followed a standardised
format in line with the guidelines produced by the Royal
College of Pathologists,11 which include tumour type and
differentiation, depth of tumour infiltration and degree of
tumour regression as laid out by the Mandard criteria.12
Number of nodes recovered and number found to have
nodal metastases were documented. Presence of extracap-
sular invasion, LI, VI and PNI were recorded routinely. No
specialised staining procedures were used to identify
lymphovascular infiltration. Stage groupings followed the
8th edition of TNM staging system.9
Follow-Up and Definition of Recurrence
Patients were routinely followed up for 10 years. Initial
outpatient review occurred at 3-month intervals in the first
year and 6-month intervals for the next 2 years; thereafter,
annual review was performed unless the appointment
needed expediting for clinical reasons. Disease recurrence
was investigated when prompted on clinical grounds and
confirmed by CT scans and/or endoscopically. Death due to
any cause or last clinic review or general practitioner visit
was used as the end point.
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Statistical Analysis
Statistical calculations were performed by SPSS soft-
ware, version 24.0 (SPSS, Chicago, IL). Categorical data
were compared using the Chi-squared or Fisher’s exact
tests, and a Mann–Whitney U test was used to compare
continuous variables. Multivariable Cox regression analy-
sis was carried out to identify independent prognostic
factors. All factors from the univariable analysis with
p value\ 0.10 were entered into the multivariable analy-
sis. p values\ 0.05 (two-sided) were considered
statistically significant.
RESULTS
Between June 2003 and June 2016, 252 patients
underwent either total or subtotal gastrectomy after
neoadjuvant therapy for adenocarcinoma of the stomach.
Multiple treatment regimens were used in the present study
determined by the standard of care and recruiting trials in
progress at the time of each patient’s treatment. All patients
received neoadjuvant therapy, although not all completed
all planned cycles. Seven patients underwent surgery with
palliative intent and/or underwent palliative resections due
to intraoperative findings of incurable disease and were
excluded from analysis. Two patients died within 90 days
(both during their index hospital admission for surgery) and
were excluded. LI, VI and PNI were reported in all spec-
imen samples.
Clinicopathological characteristics of the study popula-
tion are presented in Table 1. Of the 243 patients included,
171 (70%) were male; median age was 67 years
(24–81 years). Total gastrectomy was carried out in 146
patients (60%) due to proximity of tumour to gastro-oe-
sophageal junction or because of a diffuse-type cancer. The
remaining 97 patients underwent subtotal gastrectomy. All
patients in the present study were diagnosed with adeno-
carcinoma. Clinical staging indicated that 224 patients
(92%) were assessed as being cT3 or greater, with 204
(84%) suspected to have lymph node involvement
(cN1 ?).
After neoadjuvant therapy and surgical resection with
D2 lymphadenectomy, pathological examination revealed
that eight patients (3%) had received an R1 (microscopic
presence of tumour at the resection margin) resection. A
median number of 32 (10–142) nodes were resected.
Overall, 117 tumours (48%) were regarded as ypT3 or
worse and 136 patients (56%) had nodal involvement
(ypN1 ?).
Lymphovascular Invasion (LI)
Clinicopathological characteristics of patients according
to presence or absence of lymphovascular invasion are
presented in Table 2. Of the 243 patients, 129 (53%) were
found to have LI, which was associated with more
advanced ypT and ypN categories, an increased number of
positive nodes post-neoadjuvant therapy and presence of
VI and PNI (p\ 0.0001). In addition, there was an asso-
ciation with clinical tumour (cT) stage (p\ 0.047).
Venous Invasion (VI)
Clinicopathological characteristics of patients according
to presence or absence of venous invasion are presented in
Table 2. Of the 243 patients, 107 (44%) were found to have
VI, which was associated with more advanced ypT and
ypN categories, an increased number of positive nodes
post-neoadjuvant therapy and presence of LI and PNI (all
p\ 0.0001). There was also an association of patients
undergoing total gastrectomy being more likely to have VI
TABLE 1 Clinico-pathological characteristics of patients
undergoing either total or subtotal gastrectomy following
neoadjuvant treatment
Number of patients 243
Age (years) 67 (24–81)
Gender
Male 171
Female 72
Tumour location
Distal (STG) 97
Proximal (TG) 146
cT stage/ypT stage
cTx/ypT0 5 (2%) 17 (7%)
cT1/ypT1 4 (2%) 31 (13%)
cT2/ypT2 10 (4%) 78 (32%)
cT3/ypT3 135 (56%) 87 (36%)
cT4/ypT4 89 (37%) 30 (12%)
cNsStage/ypN stage
cN0/ypN0 39 (16%) 107 (44%)
cN1/ypN1 140 (58%) 52 (21%)
cN2/ypN2 52 (21%) 37 (15%)
cN3/ypN3 12 (5%) 47 (19%)
Radicality
R0 235
R1 8
Median number of resected nodes 32 (10–142)
Median number of positive nodes 1 (0–30)
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rather than those patients undergoing subtotal gastrectomy
(p\ 0.042).
Perineural Invasion (PNI)
Clinicopathological characteristics of patients according
to presence or absence of perineural invasion are presented
in Table 2. Of the 243 patients, 116 (48%) were found to
have PNI, which was associated with more advanced ypT
and ypN categories, an increased number of positive nodes
post-neoadjuvant therapy and presence of LI and VI
(p\ 0.0001). There was also an association of patients
undergoing total gastrectomy being more likely to have
PNI rather than those patients undergoing subtotal gas-
trectomy (p\ 0.029).
Survival Analysis
Death irrespective of cause was regarded as the primary
outcome measure. Kaplan–Meier plots for overall survival
according to ypN stage are shown in Fig. 1. Survival
curves comparing when each of LI, VI and PNI were or
were not present are shown in Fig. 1, alongside comparable
graphs of the N0 disease cohort. Survival curves illustrat-
ing the effect of cumulative presence of one, two and three
invasion factors are shown in Fig. 1g, h. Results of uni-
variable and multivariable analyses (with respect to
survival) are presented in Table 3.
Univariable analysis demonstrated that patients in our
study had poorer overall survival following subtotal rather
than total gastrectomy (HR, 1.575, CI 1.04–2.385,
p = 0.032). Survival decreased as ypT stage increased (HR,
1.905, CI 1.544–2.351, p\ 0.001) or ypN stage increased
(HR, 1.861, CI 1.581–2.19, p\ 0.001). Survival was
poorer in the small number of patients who received R1
resection (HR, 3.273, CI 1.426–7.51, p = 0.005). Presence
of LI, VI and PNI was associated with worse survival
outcomes (LI: HR, 2.947, CI 1.905–4.558; VI: HR, 2.66,
CI 1.779–3.978; PNI: HR, 3.846, CI 2.486–5.95; all
p\ 0.001), and the effect was cumulative, as seen on the
survival curves in Fig. 1. Multivariable analysis revealed
that ypT stage, ypN stage and PNI were all independent
predictors of survival (ypT: HR, 1.353, CI 1.054–1.738,
p = 0.018; ypN: HR, 1.526, CI 1.277–1.825, p\ 0.001;
PNI: HR, 2.113, CI 1.306–3.419, p = 0.002).
The impact of presence of LI, VI and PNI was evaluated
for those patients with no histopathological evidence of
lymph node involvement (ypN0, Fig. 1). This demon-
strated 5-year survival of 88% for those with zero invasion
factors present (LI, VI or PNI). This dropped to 84% with
one factor present, 72% with two factors present and 56%
when all three were present.
Adjuvant Treatment
Fifty-two patients received at least one course of post-
operative therapy. There was no significant difference in
survival between the two cohorts. Five-year survival was
57% for those not receiving adjuvant treatment compared
with 56% for those who received at least one cycle
(p = 0.747).
DISCUSSION
Gastric cancer is an aggressive malignancy in which
most patients treated with surgical resection develop dis-
ease recurrence, with a recent meta-analysis showing that
5-year survival for patients undergoing surgery is 42% if
given neoadjuvant therapy and only 30% if not.13 The
present study indicates that presence of LI, VI and/or PNI
is associated with poorer survival in patients with gastric
adenocarcinoma who are treated with neoadjuvant therapy
followed by gastrectomy with D2 lymphadenectomy, with
PNI having prognostic significance independent of lymph
node status. The reported prevalence of LI, VI and PNI is
widely distributed, with PNI being reported between 2%
and 48%, VI 7–44% and LI 10–91%. However, these
values correspond to chemotherapy-naı¨ve patients.14–16
Patients with gastric cancer who undergo surgery are
staged by the TNM system. The importance of the number
of involved nodes is reported in the 7th4 and 8th9 editions
of the TNM system, and our data reflect this, as seen in
Fig. 1. Pre-treatment clinical staging guides prognostica-
tion and choice of treatment options that are discussed with
patients; however, our analysis demonstrates minimal
association between clinical staging and presence of LI, VI
and PNI. There is an association between ypT and ypN
stage and LI, VI and PNI post-neoadjuvant therapy. A
combination of these factors is associated with poorer
survival, an important finding given that this study
demonstrates that presence of one form of invasion
increases the risk of other forms being present. This study
suggests that presence of LI, VI and/or PNI in the surgical
specimen is an indicator for aggressive disease behaviour
that should be taken into consideration along with ypT and
bFIG. 1 Survival curves of each factor and corresponding N0 disease:
a lymphatic invasion (p\ 0.001), b lymphatic invasion in N0 disease
(p = 0.033), c perineural invasion (p\ 0.001), d perineural invasion
in N0 disease (p = 0.04), e venous invasion (p\ 0.001), f venous
invasion in N0 disease (p = 0.169), g number of factors present
(p\ 0.001) and h number of factors present in N0 disease
(p = 0.038)
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ypN stage. Evaluation of survival curves in those with N0
disease demonstrated similar, albeit less pronounced, out-
comes to those in the entire cohort. Whilst a statistical
significance remains with each factor (except VI), the
change in significance may be due to the smaller dataset of
these patients. The present study provides an insight into
the survival outcomes associated with LI, VI and PNI in a
large series of gastric adenocarcinoma patients who have
undergone neoadjuvant therapy followed by surgery. Many
previous studies have reported that LI, VI and PNI are
adverse prognostic factors in other cancers, such as in
colorectal,17 gynaecological,18 breast19 and pancreatic20
cancers. In gastric cancer, LI,21 VI22 and PNI23 have all
been reported as adverse prognostic factors, although this is
predominately in patients who have not received neoadju-
vant therapy. Jhawer et al.24 reported that perineural
invasion was associated with worse outcomes in a study of
38 post-neoadjuvant patients, and Zhu et al.25 reported LI
and PNI (but not VI) data for 192 post-neoadjuvant
patients, showing worse survival if one factor was present,
but with no assessment of the additive risk of multiple
factors. The present study confirms and expands on these
previous findings by establishing that LI, VI and PNI are
individually associated with poorer survival outcomes,
with PNI acting independently of other predictors of sur-
vival. The present study also demonstrates that survival
worsens as the total number of these histopathological
factors increases. This is in good agreement with what has
been seen in oesophageal adenocarcinoma.5
In addition, the association between combined LVPNI
and survival occurs even in patients with no tumours
detected in the surgically resected lymph nodes (ypN0
subgroup). Patients in this subgroup have substantially
better survival than those with even small numbers of
positive nodes. In the present study, 44% of patients had no
residual nodal disease, and our analysis of this subgroup
suggests that survival outcomes can be further stratified
using LVPNI (Fig. 1). The present study demonstrates that,
in the ypN0 subgroup, presence of multiple LVPNI factors
(despite no positive nodes) is associated with significantly
worse survival outcomes. Patient compliance with adjuvant
therapy is often poor, and multi-disciplinary teams may
find the additional prognostic information provided by
LVPNI factors to be useful in encouraging take-up of
adjuvant therapy, especially in what might otherwise be
considered low-risk disease on a purely TNM basis.
Presence of LVPNI may be useful when stratifying
patient populations in future studies assessing the efficacy
of adjuvant regimens. These factors also have prognostic
potential in pre-operative patients for whom this informa-
tion exists, for example in patients who have had
endoscopic mucosal resection biopsies22,26,27 or in those
whose simple biopsies happen to include evidence ofT
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LVPNI. Further, these factors may help identify patients
with poorer prognosis. In those for whom neoadjuvant
treatment has had apparently little impact (e.g. TRG 4/5), it
may help support a different adjuvant modality such as
chemoradiotherapy. However, this highlights a potential
area for future work.
In conclusion, these findings suggest that presence of LI,
VI and PNI after neoadjuvant therapy followed by gas-
trectomy is associated with poorer prognosis. These factors
should be incorporated in standard pathology reports and
should be considered by multi-disciplinary teams when
identifying patients at higher risk of disease recurrence or
when considering the need for adjuvant therapy. This may
be particularly useful in decision-making, when multiple
factors are present, for node-negative patients who other-
wise might be considered relatively low risk for recurrence.
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